Accessing the Cells

Mesenchymal Stem Cells are a group of cells that exist in various tissues of the body, such as bone marrow and fat, and are present from birth. What’s interesting about these cells is that they have three properties. They are anti-inflammatory, immunomodulatory, and regenerative. This means that they have the potential to improve or prevent many chronic diseases. MSCs help restore old and damaged cells via their tissue regenerative properties. They also reduce inflammation by regulating the immune response to stable levels. As inflammation is believed to be the root cause of multiple diseases, the anti-inflammation property plays a vital role in the therapeutic use of MSCs.

Bone marrow derived MSCs have a long history of use in scientific research. For example, a metanalysis was published in E Clinical Medicine where more than 55 trials concluded that MSC treatment continues to appear safe.

Clinical trials are research studies performed on people that are aimed at evaluating a medical, surgical, or behavioral intervention. They are the primary way that researchers find out if a new treatment, such as a new drug, is safe and effective in people.

Autologous stem cell treatments use cells derived from the patient's own body. In practice, this often involves extracting MSCs from the fat tissue and injecting the patient with a concentrate including stem cells from the fat. This treatment option is widespread today since it is not classified as a medicinal product. This however also means that there is no control from medical authorities such as EMA and FDA.

Allogeneic stem cell treatments use the cells obtained from a donor.

There are various advantages with allogeneic MSC treatments produced by companies that follow the EU or US regulations. The quality is strictly regulated and controlled, meaning that we can be certain that the patient receives the intended amount and potency of cells. There is data indicating that MSCs from younger people are more potent than from older ones. One donor can provide enough cells to more than 100 patients.

MSCs are utilised or under investigation for a broad spectrum of conditions. As a manufacturer, we advise anyone considering stem cell therapies or participation in clinical trials to seek guidance from their healthcare provider.

MSCs treatments can be administered through various treatment methods. Typically, these treatments are performed either systemically or through a local injection or intravenous infusion.

Currently, we do not offer any stem cell treatments for commercial use. Our Mesenchymal Stem Cells (MSCs) are exclusively available to eligible participants enrolled in our subsidiary Cellcolabs Clinical or our partners clinical trials.